Dendritic cells (DCs) are potent antigen presenting cells that are uniquely effective in generating primary immune responses. DCs that are manipulated to present tumor antigens induce antitumor immunity in animal models and preclinical human studies. A myriad of strategies have been developed to load tumor antigen effectively onto DCs. DC-tumor fusion presents a spectrum of tumor-associated antigens to helper T-and cytotoxic T-cell populations in the context of DC-mediated costimulatory signals. In this study, fusion cells (FCs) were generated with MCA-102 fibrosarcoma cells and murine bone marrow-derived myeloid DCs. The FCs coexpressed the DC-derived MHC class II and costimulatory molecules. The FCs also retained the functional properties of DCs and stimulated syngeneic T cell proliferation and interferon-(IFN-) production. Significantly, the results show that syngeneic T cells are primed by FCs to induce MHC class I-dependent lysis of MCA-102 fibrosarcoma. These findings indicate that fusions of tumor cells and DCs activate T-cell responses against syngeneic tumors.
1,2) Functionally, DCs can progress from an immature state in which they take up and process antigens efficiently but activate T cells poorly, to a mature state in which such features are inverted. 3, 4) Recently, DCs pulsed with synthetic tumor-associated antigens (Ag), [5] [6] [7] or tumor lysate 8, 9) or engineered with recombinant adenoviral vectors to produce interleukin-12 (IL-12) 10, 11) induced CD4 þ and CD8 þ Ag-specific responses both in vitro and in vivo in mice and humans. Another approach to the induction of primary antitumor immunity is through the generation of fusions between tumor cells and DCs. 12) In this strategy, multiple tumor antigens, including some as yet unidentified, are processed endogenously and presented by MHC class I pathways in the context of costimulatory signals. In an animal model, fusions between murine carcinoma cells and syngeneic DCs coexpressed MUC1 tumor-associated antigen and DC-derived MHC class II, CD80 and CD86 molecules. Animals with established pulmonary metastases vaccinated with the fusion cells were rendered disease-free. 12) Similar results have been obtained by vaccinating mice and/or humans with fusions of DCs and other tumor-cell types. [13] [14] [15] In this study, it was examined whether functionally active fusions can be prepared from MCA-102 fibrosarcoma cells and murine DCs. We identified the generation of fusion cells (FCs) that express both costimulatory and MHC class II molecules. FCs are functionally active in stimulating syngeneic T cell proliferation and, importantly, induce cytotoxic T lymphocyte (CTL) activity directed against MCA-102 tumor cells.
Materials and Methods
Reagents. Recombinant murine (rm) GM-CSF and rmIL-4 were purchased from R&D Systems (Minneapolis, MN). Mitomycin C and PKH-67 were purchased from Sigma (St. Louis, MO). FITC-and PE-conjugated mAbs used to detect cell surface expression of CD11c (HL3), CD80 (16-10A1), CD86 (GL1), IA b -chain (MHC II; 25-9-17), and H2K b (MHC I; AF6-88.5) by flow cytometry, as well as isotype matched control mAbs, were purchased from PharMingen (San Diego, CA).
Generation of bone marrow-derived DCs. DCs were generated from murine bone marrow cells as described by Crowley et al., 16) with minor modifications. Briefly, bone marrow was flushed from the long bones of C57BL/6 mice (Korean Institute of Chemistry Technology, Daejeon, Korea) and depleted of red cells with ammonium chloride. The cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 5 Â 10 À5 M 2-mercaptoethanol, 10 mM HEPES (pH 7.4) (all from Sigma), 20 ng/ml of rmGM-CSF, and 20 ng/ml of rmIL-4, referred as complete medium (CM). On day 0, 3 Â 10 6 cells were seeded per 6-well plate (3 ml/well) and incubated at 37 C in 5% CO 2 in air. On days 2 and 4, floating cells were gently removed and fresh CM was added. On day 6, culture supernatant was aspirated and replaced with CM. To obtain highly purified populations for subsequent analysis, DC were labeled with beadconjugated anti-CD11c mAb (Miltenyi Biotec, Auburn, CA) followed by positive selection through paramagnetic columns (LS columns, Miltenyi Biotec) according to the manufacturer's instructions. A DC purity of 90-95% was consistently achieved.
Cell fusion. DCs were mixed with MCA-102 fibosarcoma cells at a 3:1 ratio and incubated in serum-free RPMI 1640 containing 50% polyethylene glycol for 5 min. After being slowly diluted with serum-free RPMI medium 1640, the cells were washed, resuspended in RPMI medium 1640 supplemented with 10% FBS and 20 ng/ml GM-CSF, and incubated at 37 C for 7-14 d.
Flow cytometric analysis.
A flow cytometric analysis, as described by Kodaira et al., was performed. 17) Briefly, for 15 min at 4 C, cells (5 Â 10 5 ) were first immersed in a staining buffer (PBS with 2% FBS and 0.1% sodium azide) containing anti-CD16/CD32 mAb (PharMingen) in order to block nonspecific binding of Igs, and then stained with mAb for 30 min at 4 C. Cells stained with the appropriate isotype-matched Ig were used as negative controls. After staining, the cells were fixed with 2% w/v paraformaldehyde and analyzed using a FACSCallibur (Becton-Dickinson, San Jose, CA). In a parallel experiment, the MCA-102 fibrosarcoma and DCs were stained with green fluorescent dye PKH-67 (Sigma) and CD11c-PE, respectively. The resulting cells were observed under a fluorescence microscope and also analyzed by flow cytometry.
Syngeneic T-cell stimulation and IFN-production.
Responder T cells used for syngeneic T-cell reaction were isolated with a MACS column (Miltenyi Biotec, Bergisch Gladbach, Germany) passing through mononuclear cells from C57BL/6 mice. As determined by staining with FITC-conjugated anti-CD3 antibody (PharMingen), they were composed mainly of CD3 þ cells (> 93%). DCs, MCA-102, MCs and FCs were exposed to 50 mg/ml mitomycin C (Sigma) for 1 h and added in graded doses to 1 Â Lactate dehydrogenase (LDH) assay and tumor rejection assay. C57BL/6 mice were immunized twice over a 1-week interval with unpulsed-DCs, MCA-102, mixed cells (MCs) or fusion cells (FCs). The cells (1 Â 10 6 cells/100 ml/mouse) were injected subcutaneously into the right flank. After the last immunization, the spleens were excised and single-cell suspensions were prepared. The splenocytes were re-stimulated in vitro with unpulsed-DCs, MCA-102, MCs, or FCs pretreated with mitomycin C (50 mg/ml) at 37 C for 30 min. Five days after re-stimulation, the MCA-102 cells (2 Â 10 5 cells/ml) were incubated with 1 Â 10 6 cells/ ml splenocytes (effector cells:target cells = 10:1, 25:1, and 50:1) for the final 24 h. The activities of LDH released into the culture supernatants were measured with LDH-cytotoxic test kit (Roche Molecular Biochemicals, Indianapolis, IN). A substrate mixture containing tetrazolium salts was added, and then incubated for 3 h. The formazan dye was quantitated by measuring the absorbance at 490 nm. For a tumor rejection assay, one week after the final vaccination, 3 Â 10 5 MCA-102 fibrosarcoma were inoculated into the left flank. Tumor incidence was assessed three times per week using microcalipers.
Statistical analysis. A statistical analysis was performed using the Student t test; p < 0:05 was consid- ered to be significant. The normal distribution of values, a prerequisite for using the Student t-test, was proved by the Kolmogorov-Smirnov test. The results are expressed as the means AE SD. All of the statistical analyses were performed using SPSS software version 8.0 (SPSS, Chicago, IL).
Results

MCA-102/DC fusion induces phenotypic changes
To determine whether DCs can be used in the generation of heterokaryons with tumor cells, we prepared DC from murine bone marrow cells. The DCs were first fused with MCA-102 fibrosarcoma cells. Flow cytometry and fluorescent microscopy were used where CD11c-PE-labeled DCs were visually assessed for green fluorescent PKH-67-labeled MCA-102 at a ratio of 1:1. Over 50% of the DC fused with MCA-102 (Fig. 1) . Bidimensional flow cytometry indicated that the MCA-102 cells expressed MHC class I, but not MHC class II, CD80, or CD86 molecules (Fig. 2) . By contrast, DCs expressed MHC class I, Class II, and costimulatory molecules (CD80 and CD86). The tumor cells were fused with DC and, after culturing for 7 d, the resulting population was analyzed for the presence of fusion cells. Fusion of the tumor cells to DCs resulted in the generation of MHC class II and costimulatory molecules.
FCs are functionally active and induce specific T cell responses
To determine whether syngeneic FCs are effective in stimulating syngeneic T cells, heterokaryons were cocultured with T cells isolated from spleen cells. To establish a control, the T cells were also cocultured with syngeneic DCs or MCA-102. Although there was no evidence of a T-cell response to syngeneic tumor, the fusion cells stimulated T-cell proliferation (Fig. 3A) . To assess the selectivity of this response, syngeneic T cells were incubated with DCs, MCA-102, MCs (a mixture of the two cell types) and FCs. The results yielded little if any evidence for T-cell stimulation by syngeneic DCs, tumor cells or MCs. By contrast, incubation of T cells with syngeneic FCs was associated with T-cell proliferation. Herein, we also investigated the influence of FCs on IFN-production. As shown in Fig. 3B , the splenocytes cocultured with DCs, MCA-102 or MCs produced moderated levels of IFN-. High levels of IFN-were measured from splenocytes cocultured with FCs (289 AE 31 pg/ml). These findings indicate that fusion of MCA-102 fibrosarcoma cells and DC results in stimulation of a specific T-cell response.
Vaccination of FCs in vivo affects MCA-102-specific CTL response
FC vaccines have been reported to trigger directly a specific CTL response. 18) To assess the induction of tumor-specific CTLs with FC vaccination, we compared their function in the lysis of tumor cells and other cell types. We used the LDH-release assay to determine the influence of FC administration on the induction of the MCA-102-specific CTL response. Spleen cells were prepared from mice on day 7 after vaccination with FC via subcutaneous routes. A cytotoxic effector was generated by coculturing splenocytes for 5 d with FCs treated with mitomycin (50 mg/ml for 1 h). As shown in Fig. 4 , a strong lytic activity against MCA-102 was elicited in cultured splenocytes from mice administered FCs. Cytotoxic activity against B16 cells and YAC-1 cells failed to be generated by vaccination with FCs. To evaluate tumor rejection further by FC vaccination, effector cells pretreated with anti-MHC I MAbs were used. The finding that preincubation of the targets with an anti-MHC class I antibody resulted in abrogation of syngeneic MCA-102 tumor cell lysis indicated that the killing was MHC class I-restricted (Fig. 5) . By contrast, the anti-MHC class I antibody itself had little if any A, T cells were cultured with DCs, MCs, MCA-102 or FCs at the indicated ratios of T cells to stimulators. B, IFN-production was analyzed using intracellular cytokine staining after co-culture. All of the experiments were performed in triplicate, and the results were calculated as the mean AE SD. A typical result of one out of three experiments performed is shown. Significance was determined using Student's t-test (Ã, p < 0:05 vs. DC).
effect on the lysis of the other cell types. These results suggest that tumor-reactive effector cells induced by FCs vaccination are CD8 þ T cells with cytotoxic activity restricted to MHC class I. Taken together, these results indicate that the induction of an antigen-specific CTL response is greatly affected by the administration of FC.
FC vaccination suppressed tumor growth in vivo
To examine whether FC can promote antitumor activity in vivo, mice pretreated with DCs, MCA-102, MCs or FCs were challenged 7 d before administration of MCA-102. Most of the mice pretreated with DCs, MCA-102 or MCs showed no resistance against tumor growth (Fig. 6) . By contrast, in mice pretreated with FCs, there was a significantly delay in tumor development and a reduced tumor incidence. Eight of 10 mice were free of tumors at day 40 after injection of MCA-102 (Table 1) . These results suggest that FC vaccination significantly induces rejection of tumor growth. MCA-102 cells pretreated with anti-MHC I were used as targets in the cytotoxic assay, under conditions of a fixed effector/target ratio (E:T = 50:1). For each control, the target cells were pretreated with non-specific mouse IgG. The percent ratios of the LDH-release counts in each experiment with MAb pretreatments against those in the controls are shown as the percent cell lysis. All of the experiments were performed in triplicate, and the results were calculated as the mean AE SD. A typical result of one out of three performed experiments is shown. Significance was determined using Student's t-test (Ã, p < 0:05 vs. + anti-MHC class I). 
Discussion
Despite the presence of tumor-specific antigens with a capacity to be recognized by CTLs, clinical responses are ineffective in eradicating tumor cells. The development of immune tolerance toward malignant cells is due in part to the likelihood that tumor antigens are presented to the immune system in the absence of essential costimulatory signals necessary for the priming of T-cell responses. 2, 19) Therefore, T cells with the capability of recognizing these antigens become inactivated. A major focus of cancer immunotherapy has been the attempt to reverse tumor-induced anergy through presentation of an antigen in the context of appropriate secondary signals. A novel strategy for inducing effective antitumor immunity is through the use of hybridomas created by the fusion of DCs with tumor cells. In this approach, an immunogenic cell is created that expresses tumor antigens and DC-derived costimulatory molecules. Multiple tumor antigens, including some yet unidentified, can be presented simultaneously in the appropriate MHC context. This strategy is likely to induce a polyclonal CTL response that would optimize the possibility of inducing tumor rejection. 18) Vaccination with FCs generated from DCs and tumor cells can induce tumor-specific CTL responses and protect immunized animals against tumor challenge, and pre-established tumors can regress; 6, 9, 15) hence several clinical trials were begun. 2, 7) Vaccination with FCs appears to be an attractive approach to cancer immunotherapy since multiple tumor antigens, involving both known and unknown antigens, can be presented to the immune system. Presentation of the entire repertoire of tumor antigens might enhance anti-tumor immunity and minimize the emergence of resistant variants. Immunization with multiple tumor antigens should be more effective than with a single epitope. Furthermore, fusion of DCs with tumor cells would seem to have several advantages as compared to other currently used strategies for developing DC-based vaccines such as loading DCs with tumor antigenic proteins or peptides.
The present findings indicate the generation of DCs and syngeneic firbrosarcoma. In preclinical models, vaccination with DC/tumor fusion cells has provided an approach in which both known and unidentified tumor antigens are presented in the context of costimulatory signals. Moreover, a fusion cell vaccine has been shown to reverse immunologic unresponsiveness to a tumorassociated antigen and to induce rejection of established metastases. The results of the present studies extend these observations by indicating that DC/fibrosarcoma fusions stimulated syngeneic T cells, which are otherwise unresponsive to autologous firbosarcoma. Significantly, the fusion cells were effective in inducing antitumor CTLs, which lyse fibrosarcoma cells by an MHC class I-restricted mechanism. Characterization of the peptides recognized by these CTLs can be used to identify tumor-associated antigens that are the targets of the immune response. In addition, the findings indicate that activation of immunity against tumor-associated antigens by vaccination with DC/tumor cell fusions has potential applicability in the field of antitumor immunotherapy. 
